reconstitution raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-09-28. Anything still debated is marked as such rather than presented as settled.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Published research on the intact protein is substantial, covering actin regulation, cell migration, and wound models. Research using the heptapeptide fragment specifically is far smaller, and much of the circulating material originates in supplier documentation rather than peer-reviewed reports. Where fragment studies do exist, they often employ different sequences, chain lengths, or terminal modifications, which complicates direct comparison across papers. Readers encountering claims about TB-500 should therefore separate evidence about thymosin beta-4 from evidence about the fragment itself.
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H68N10O14 | Calculated for the acetylated heptapeptide |
| Molecular weight | ~889 Da | Monoisotopic mass approximately 889.0 Da |
| Amino acid sequence | Ac-LKKTETQ | N-terminal acetylated seven-residue peptide |
| Appearance | White to off-white powder | Typically supplied as a lyophilized solid |
| Solubility class | Water-soluble | Peptides of this size generally dissolve in aqueous media |
Identity and purity are assessed with a small set of standard techniques. Reverse-phase high-performance liquid chromatography gives a purity estimate from peak area, usually recorded at 214 or 220 nanometers, where the peptide bond absorbs. Mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidized species. Amino acid analysis or tandem mass spectrometry sequencing can verify the sequence itself. Additional quality attributes include water content, residual trifluoroacetic acid carried over from purification, and endotoxin where the material is intended for biological work.
The compound is most often distributed as a lyophilized powder, appearing white to off-white and forming a loose cake or fluffy solid. It is hygroscopic to some degree, so brief exposure to humid air can add water weight and complicate weighing. The peptide dissolves readily in water and in neutral aqueous buffers, and aqueous solubility is generally described as high, well above the concentrations used in typical assays. Some polar organic solvents are also usable, which matters when a concentrated stock is prepared before dilution into buffer.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
Identity and purity checks for peptide material typically combine reversed-phase high-performance liquid chromatography with mass measurement, since retention time alone cannot confirm a sequence. Mass measurement verifies the expected molecular mass within instrument tolerance, while chromatographic peak area provides a purity estimate. Anti-doping analysis of urine uses related but more sensitive workflows, sometimes after solid-phase extraction. For research material, batch documentation, certificate content, and independent testing are common points of scrutiny, because supply chains outside pharmaceutical regulation vary widely in the paperwork they provide.
Reconstitution of a lyophilized peptide is normally done with sterile water or a suitable buffer under aseptic conditions. Adding solvent down the vial wall and allowing gentle dissolution instead of vigorous vortexing reduces the chance of aggregation, which can lower the effective concentration of the resulting solution. Concentrated stocks are usually diluted into working buffer shortly before use. Because no standard preparation protocol exists for TB-500 specifically, laboratories adapt general peptide handling practice, and reported results may reflect differing preparation choices.
Dry peptide powder is commonly kept at −20 °C in a desiccated container away from light, a practice that limits moisture uptake and oxidation. Once dissolved, solutions are generally held at 2–8 °C for short periods or frozen at −20 °C or lower for longer storage, with repeated freeze-thaw cycles avoided. Hydrolysis and oxidation are the main degradation routes for peptides in solution, and both accelerate at higher temperature or extreme pH. Published stability data specific to TB-500 are limited, so shelf life should be treated as uncertain.
Purity is normally assessed by reversed-phase HPLC, with the main peak reported as a percentage of total peak area, while identity is confirmed by mass spectrometry. Electrospray and MALDI-TOF instruments are both used, and the observed mass is compared with the value calculated from the stated sequence. Ion-exchange or size-exclusion methods appear where aggregation or charge variants are of interest. Water content, counter-ion content and residual trifluoroacetate from purification are separate variables that can shift the measured mass and should be weighed when reading a certificate of analysis.
Research peptides are typically supplied as a white to off-white lyophilised powder in a sealed vial. The dry solid is more stable than a solution and is normally kept refrigerated or frozen until use. Dissolution is usually done in water, phosphate-buffered saline or a similar aqueous medium, depending on the assay. Because the material is hygroscopic and easily contaminated, opening vials in a low-humidity environment and recording the lot number before use are standard laboratory practices.
Once in solution, short peptides are generally less stable than the dry powder, and repeated freeze-thaw cycles are a common cause of loss. Laboratory guidance usually calls for aliquoting on first dissolution and storing aliquots at -20 °C or below, away from light. Adsorption to plastic and glass surfaces can lower measured concentration, particularly at low concentrations, so container material and buffer choice can affect results. Visible cloudiness, colour change or unexpected precipitate is a signal to re-check the material.
Interest in a possible island of stability grew throughout the 1960s, as some calculations suggested that it might contain nuclides with half-lives of billions of years. They were also predicted to be especially stable against spontaneous fission in spite of their high atomic mass. It was thought that if such elements exist and are sufficiently long-lived, there may be several novel applications as a consequence of their nuclear and chemical properties. These include use in particle accelerators as neutron sources, in nuclear weapons as a consequence of their predicted low critical masses and high number of neutrons emitted per fission, and as nuclear fuel to power space missions. These speculations led many researchers to conduct searches for superheavy elements in the 1960s and 1970s, both in nature and through nucleosynthesis in particle accelerators. During the 1970s, many searches for long-lived superheavy nuclei were conducted. Experiments aimed at synthesizing elements ranging in atomic number from 110 to 127 were conducted at laboratories around the world. These elements were sought in fusion-evaporation reactions, in which a heavy target made of one nuclide is irradiated by accelerated ions of another in a cyclotron, and new nuclides are produced after these nuclei fuse and the resulting excited system releases energy by evaporating several particles (usually protons, neutrons, or alpha particles).
== Research == More than 160 faculty members at the University of Texas Health Science Center at San Antonio are actively involved in biomedical and clinical research and educational activities that range from the molecular genetics of aging to issues of health care for the elderly population. Research at the Barshop Institute spans the continuum from basic discovery science to translational and clinical research aimed at extending healthspan and improving quality of life in older adults. Investigators study the fundamental biological processes that drive aging—including cellular senescence, mitochondrial dysfunction, metabolism, inflammation, genomic instability, and impaired tissue regeneration—and apply these discoveries to develop strategies for preventing or treating age-related diseases. Major areas of investigation include Alzheimer's disease and related dementias, cardiovascular disease, type 2 diabetes and metabolic disorders, cancer, frailty, sarcopenia, osteoporosis, and age-associated liver disease. Through the integration of laboratory research, animal models, clinical trials, and population-based studies, Barshop Institute scientists are advancing new therapeutic approaches that target the underlying mechanisms of aging to delay the onset of chronic disease, preserve physical and cognitive function, and promote healthy longevity.
Again: multiparameter analysis best reveals a pathological state. As these technologies improve, the disease profiles should be continually related to respective gene expression changes. Due to the above-mentioned problems plasma proteomics remained challenging. However, technological advancements and continuous developments seem to result in a revival of plasma proteomics as it was shown recently by a technology called plasma proteome profiling. Due to such technologies researchers were able to investigate inflammation processes in mice, the heritability of plasma proteomes as well as to show the effect of such a common life style change like weight loss on the plasma proteome.
In 1996, the World Health Organization (WHO) launched the EMF (ElectroMagnetic Fields) Project to bring together current knowledge and available resources from key international and national organizations and scientific institutions on electromagnetic fields. The German Federal Office for Radiation Protection (BfS) published the following recommendation in 2006:
Sources: en.wikipedia.org
==== US policy vs EU policy ==== The US Food and Drug Administration (FDA) approves the use of meloxicam in cats only in injectable form and only as a one-time injection given before surgery. It does not approve meloxicam oral suspension for cats and it does not approve meloxicam spray for cats because after reviewing numerous reports of meloxicam side effects in cats, it has identified many cases of acute renal failure and death and has added the following boxed warning to the prescription label: "Repeated use of meloxicam in cats has been associated with acute renal failure and death. Do not administer additional injectable or oral meloxicam to cats. See Contraindications, Warnings, and Precautions for detailed information." In contrast, in the European Union and other continents or countries, the use of the drug in cats is allowed with no such warning. The product instruction leaflet for meloxicam for cats in the form of oral suspension 0.5 mg/ml states that: "Typical adverse reactions of NSAIDs such as loss of appetite, vomiting, diarrhoea, faecal occult blood, apathy, and renal failure have occasionally been reported. These side effects are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal."
=== History of isolation === Didymin was first described in 1965 by German scientists Carl Heinz Brieskorn and Gerhard Meister, who identified isosakuranetin-7-rhamnosidoglucoside in the leaves of Monarda didyma L. The structure of didymin was subsequently clarified and confirmed by total synthesis in 1968 by Wagner, Hörhammer, Aurnhammer, and Farkas.
== Quinine content == Medicinal tonic water originally contained only carbonated water and a large amount of quinine. Most modern tonic waters contain comparatively less quinine, and are often enhanced by citrus flavours. As a result of the lower quinine content, tonic water is less bitter. It is also usually sweetened, often with the addition of high-fructose corn syrup or sugar. Some manufacturers also produce diet (or "slimline") tonic water, which may contain sugar substitutes such as aspartame. Traditional-style tonic water with high amounts of quinine and carbonated water is less common, but may be preferred by those who desire the bitter flavour. In the United States, the US Food and Drug Administration (FDA) limits the quinine content in tonic water to 83 ppm (83 mg per litre). In Europe, the limit is 100 mg/L, which is 0.25–0.50% of the original strength. The therapeutic dose of quinine is 10 mg per kg of body mass every eight hours for effective malaria prevention (2,100 mg daily for a 70-kilogram (150 lb) adult). Until about 2010, quinine was often recommended as a relief for leg cramps, although medical research suggested some care was needed in monitoring doses. Because of quinine's risks, the FDA cautions consumers against using "off-label" quinine drugs to treat leg cramps.
=== Reducing filament evaporation === During ordinary operation, the tungsten of the filament evaporates; hotter, more-efficient filaments evaporate faster. Because of this, the lifetime of a filament lamp is a trade-off between efficiency and longevity. The trade-off is typically set to provide a lifetime of 1,000 to 2,000 hours for lamps used for general illumination. Theatrical, photographic, and projection lamps may have a useful life of only a few hours, trading life expectancy for high output in a compact form. Long-life general service lamps have lower efficiency, but prior to the development of compact fluorescent and LED lamps they were useful in applications where the bulb was difficult to change. Irving Langmuir found that an inert gas, instead of vacuum, would retard evaporation. General service incandescent light bulbs over about 25 watts in rating are now filled with a mixture of mostly argon and some nitrogen, or sometimes krypton. While inert gas reduces filament evaporation, it also conducts heat from the filament, thereby cooling the filament and reducing efficiency. At constant pressure and temperature, the thermal conductivity of a gas depends upon the molecular weight of the gas and the cross sectional area of the gas molecules. Higher molecular weight gases have lower thermal conductivity, because both the molecular weight and cross sectional area are higher. Xenon gas improves efficiency because of its high molecular weight, but is also more expensive, so its use is limited to smaller lamps.
Chemical kinetics is the study of the rates at which systems that are out of equilibrium change under the influence of various forces. When applied to materials science, it deals with how a material changes with time (moves from non-equilibrium to equilibrium state) due to application of a certain field. It details the rate of various processes evolving in materials including shape, size, composition and structure. Diffusion is important in the study of kinetics as this is the most common mechanism by which materials undergo change. Kinetics is essential in processing of materials because, among other things, it details how the microstructure changes with application of heat.
Sources: en.wikipedia.org
TB-500 is a synthetic heptapeptide corresponding to a fragment of thymosin beta-4. It is used in laboratory research and is not an approved drug.
No. Thymosin beta-4 is a 43-amino-acid protein, while TB-500 represents only a short N-terminal segment. The two should not be treated as interchangeable in experimental design.
It is often called a thymosin beta-4 fragment, Tβ4 fragment, or Ac-LKKTETQ. The name TB-500 is mainly a commercial or catalog label rather than a formal chemical name.
Most listings describe it as a short acetylated peptide with the sequence Ac-LKKTETQ, presented as a region of thymosin beta-4. The label is a trade-style name rather than a standardized chemical name, so the exact content of a given vial depends on the supplier.